Kairos Pharma (NYSEAMERICAN:KAPA) Trading Down 2.2% – What’s Next?

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA)’s stock price was down 2.2% during trading on Wednesday . The company traded as low as $0.8260 and last traded at $0.84. Approximately 82,735 shares traded hands during mid-day trading, a decline of 43% from the average daily volume of 144,729 shares. The stock had previously closed at $0.8592.

Analysts Set New Price Targets

Separately, D. Boral Capital reissued a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $8.33.

Kairos Pharma Stock Down 2.2%

The company has a market capitalization of $17.49 million, a price-to-earnings ratio of -2.71 and a beta of 2.20. The stock has a 50 day simple moving average of $0.98 and a 200 day simple moving average of $0.98.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KAPA. Armistice Capital LLC acquired a new stake in shares of Kairos Pharma in the first quarter valued at approximately $1,314,000. XTX Topco Ltd bought a new position in Kairos Pharma in the 2nd quarter worth approximately $44,000. Finally, Two Sigma Investments LP acquired a new stake in Kairos Pharma in the 3rd quarter valued at approximately $54,000.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.